EirGenix Inc. (TPEX:6589)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
64.50
+2.80 (4.54%)
May 14, 2025, 2:32 PM CST
-19.58%
Market Cap 19.70B
Revenue (ttm) 1.01B
Net Income (ttm) -698.34M
Shares Out 305.41M
EPS (ttm) -2.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 808,794
Average Volume 279,300
Open 62.30
Previous Close 61.70
Day's Range 62.30 - 65.40
52-Week Range 52.70 - 100.50
Beta 0.37
RSI 52.15
Earnings Date May 9, 2025

About EirGenix

EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical and quality control, cGMP manufacturing mammalian and microbial system, and antibody-drug conjugate services. It is also involved in the development of EG12014/EGI014, a Trastuzumab biosimilar, indicated for the treatment of cancer and currently under biologics license application status; EG1206A, a Pertuzumab biosimilar, indicated for the treatment of cancer and curr... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6589
Full Company Profile

Financial Performance

In 2024, EirGenix's revenue was 1.01 billion, a decrease of -1.34% compared to the previous year's 1.02 billion. Losses were -698.34 million, -23.70% less than in 2023.

Financial Statements

News

There is no news available yet.